The need for probiotics the using in the treatment of patients with cardiovascular diseases
https://doi.org/10.17021/1992-6499-2025-1-6-15
Abstract
This literature review shows the importance of including probiotic drugs in the treatment of patients with cardiovascular diseases. Current literature sources were analyzed using the PubMed, Science direct, Elibrary, and Google scholar databases. There are a lot of potential mechanisms of the probiotics effect on the cardiovascular system: synthesis of SCFAs, reduction of endotoxinemia in the blood, regulation of the blood coagulation system, reduction of TMAO synthesis, etc. There are many studies experimental (with laboratory animals) and clinical, that prove pathogenetically and clinically the effectiveness of the probiotic drugs using in patients with cardiac pathology. An important task for a cardiologist is the choice of a probiotic drug, its clinically effective dosage, duration of treatment, and the possibility of combination with conventional cardiac therapy
About the Authors
J. V. Chervinets
Tver State Medical University
Russian Federation
Russian Federation
Julija V. Chervinets, Dr. Sci. (Med.), Professor, Head of the Department
Tver
E. V. Stepanova
Tver State Medical University
Russian Federation
Russian Federation
Emma V. Stepanova, postgraduate student
Tver
V. M. Chervinets
Tver State Medical University
Russian Federation
Russian Federation
Vyacheslav M. Chervinets, Dr. Sci. (Med.), Professor of the Department
Tver
V. S. Belyaev
Tver State Medical University
Russian Federation
Russian Federation
Vsevolod S. Belyaev, Assistant
Tver
A. O. Schukina
Tver State Medical University
Russian Federation
Russian Federation
Aleksandra O. Schukina, student
Tver
A. S. Pogosjan
Tver State Medical University
Russian Federation
Russian Federation
Al'bert S. Pogosjan, student
Tver
References
1. Boytsov S. A., Drapkina O. M., Shlyakhto E. V., Konradi A. O., Balanova Yu. A., Zhernakova Yu. V., Metelskaya V. A., Oshchepkova E. V., Rotar O. P., Shalnova S. A. Study ESSE-R.F. (Epidemiology of cardiovascular diseases and their risk factors in the regions of the Russian Federation). Ten years later. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2021; 20 (5): 3007. doi: 10.15829/1728-8800-2021-3007 (In Russ.).
2. Shalnova S. A., Drapkina O. M., Kutsenko V. A., Kapustina A. V., Muromtseva G. A. et al. Myocardial infarction in the population of some regions of Russia and its prognostic significance. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2022; 27 (6): 4952. https://doi.org/10.15829/1560-4071-2022-4952 (In Russ.).
3. Oniszczuk A., Oniszczuk T., Gancarz M., Szymańska J. Role of Gut Microbiota, Probiotics and Prebiotics in the Cardiovascular Diseases. Molecules. 2021; 26 (4): 1172. doi: 10.3390/molecules26041172. PMID: 33671813; PMCID: PMC7926819.
4. Matsiras D., Bezati S., Ventoulis I., Verras C., Parissis J., Polyzogopoulou E. Gut Failure: A Review of the Pathophysiology and Therapeutic Potentials in the Gut-Heart Axis. Journal of Clinical Medicine. 2023; 12 (7): 2567. doi: 10.3390/jcm12072567. PMID: 37048650; PMCID: PMC10095379.
5. Janeiro M. H., Ramírez M. J., Milagro F. I., Martínez J. A., Solas M. Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients. 2018; 10 (10): 1398. doi: 10.3390/nu10101398.
6. Carmela Cosola, Maria Teresa Rocchetti, Adamasco Cupisti, Loreto Gesualdo. Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease. Pharmacological Research. 2018; 130: 132–142.
7. Lässiger-Herfurth A., Pontarollo G., Grill A., Reinhardt C. The Gut Microbiota in Cardiovascular Disease and Arterial Thrombosis. Microorganisms. 2019; 7 (12): 691. doi: 10.3390/microorganisms7120691. PMID: 31847071; PMCID: PMC6956001.
8. Mohammad S., Thiemermann C. Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. Frontiers in Immunology. 2021; 11: 594150. doi: 10.3389/fimmu.2020.594150. PMID: 33505393; PMCID: PMC7829348.
9. Violi F., Cammisotto V., Bartimoccia S., Pignatelli P., Carnevale R., Nocella C. Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. Nature Reviews Cardiology. 2023; 20 (1): 24–37. doi: 10.1038/s41569-022-00737-2. Epub 2022 Jul 15. PMID: 35840742; PMCID: PMC9284488.
10. Mawhin M. A., Tilly P., Zirka G., Charles A. L., Slimani F., Vonesch J. L., Michel J. B., Bäck M., Norel X., Fabre J. E. Neutrophils recruited by leukotriene B4 induce features of plaque destabilization during endotoxaemia. Cardiovascular Research. 2018; 114 (12): 1656–1666. doi: 10.1093/cvr/cvy130. PMID: 29800147.
11. Khan M. J., Gerasimidis K., Edwards C. A., Shaikh M. G. Role of Gut Microbiota in the Aetiology of Obesity: Proposed Mechanisms and Review of the Literature. Journal of Obesity. 2016; 2016: 7353642. doi: 10.1155/2016/7353642.
12. Kim J., Yang G., Kim Y., Kim J., Ha J. AMPK activators: mechanisms of action and physiological activities. Experimental & Molecular Medicine. 2016; 48 (4): e224. doi: 10.1038/emm.2016.16.
13. Natarajan N., Hori D., Flavahan S. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. Physiological Genomics. 2016; 48 (11): 826–834. doi: 10.1152/physiolgenomics.00089.2016.
14. Yu H., Qin L., Hu H., Wang Z. Alteration of the Gut Microbiota and Its Effect on AMPK/NADPH Oxidase Signaling Pathway in 2K1C Rats. BioMed Research International. 2019; 2019: 8250619. doi: 10.1155/2019/8250619.
15. Kamo T., Akazawa H., Suda W., Saga-Kamo A., Shimizu Y. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS One. 2017; 12 (3): e0174099. https://doi.org/10.1371/journal.pone.0174099.
16. Sun W., Du D., Fu T., Han Y., Li P., Ju H. Alterations of the Gut Microbiota in Patients With Severe Chronic Heart Failure. Frontiers in Microbiology. 2022; 12: 813289. doi: 10.3389/fmicb.2021.813289. PMID: 35173696; PMCID: PMC8843083.
17. Han Y., Gong Z., Sun G., Xu J., Qi C., Sun W., Jiang H., Cao P., Ju H. Dysbiosis of Gut Microbiota in Patients With Acute Myocardial Infarction. Frontiers in Microbiology. 2021; 12: 680101. doi: 10.3389/fmicb.2021.680101. PMID: 34295318; PMCID: PMC8290895 5.
18. Sadeghzadeh J., Vakili A., Sameni H. R., Shadnoush M., Bandegi A. R., Zahedi Khorasani M. The Effect of Oral Consumption of Probiotics in Prevention of Heart Injury in a Rat Myocardial Infarction Model: a Histopathological, Hemodynamic and Biochemical Evaluation. Iran Biomedical Journal. 2017; 21 (3): 174–181. doi: 10.18869/acadpub.ibj.21.3.174. PMID: 27874107; PMCID: PMC5392220.
19. Borshchev Y. Y., Sonin D. L., Burovenko I. Y., Borshchev V. Y., Cheburkin Y. V., Borshcheva O. V., Galagudza M. M. The Effect of Probiotic Strains on Myocardial Infarction Size, Biochemical and Immunological Parameters in Rats with Systemic Inflammatory Response Syndrome and Polymorbidity. Journal of Evolutionary Biochemistry and Physiology. 2022; 58 (6): 2058–2069. doi: 10.1134/S0022093022060321. PMID: 36573161; PMCID: PMC9773675.
20. Gan X. T., Ettinger G., Huang C. X., Burton J. P., Haist J. V., Rajapurohitam V., Sidaway J. E., Martin G., Gloor G. B., Swann J. R., Reid G., Karmazyn M. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circulation Heart Failure. 2014; 7 (3): 491–499. doi: 10.1161/CIRCHEARTFAILURE.113.000978. PMID: 2462536.
21. Wang J., Chen J., Li L., Zhang H., Pang D., Ouyang H., Jin X., Tang X. Clostridium butyricum and Bifidobacterium pseudolongum Attenuate the Development of Cardiac Fibrosis in Mice. Microbiology Spectrum. 2022; 10 (6): e0252422. doi: 10.1128/spectrum.02524-22. PMID: 36318049; PMCID: PMC9769846.
22. Sun B., Ma T., Li Y., Yang N., Li B., Zhou X., Guo S., Zhang S., Kwok L. Y., Sun Z., Zhang H. Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes. mSystems. 2022; 7 (2): e0010022. doi: 10.1128/msystems.00100- 22. PMID: 35343796; PMCID: PMC9040731.
23. Meng H., Ba Z., Lee Y., Peng J., Lin J., Fleming J. A., Furumoto E. J., Roberts R. F., Kris-Etherton P. M., Rogers C. J. Consumption of Bifidobacterium animalis subsp. lactis BB-12 in yogurt reduced expression of TLR-2 on peripheral blood-derived monocytes and pro-inflammatory cytokine secretion in young adults. European Journal of Nutrition. 2017; 56 (2): 649–661. doi: 10.1007/s00394-015-1109-5. PMID: 26621631.
24. Moludi J., Kafil H. S., Qaisar S. A., Gholizadeh P., Alizadeh M., Vayghyan H. J. Effect of probiotic supplementation along with calorie restriction on metabolic endotoxemia, and inflammation markers in coronary artery disease patients: a double blind placebo controlled randomized clinical trial. Journal of Nutrition. 2021; 20 (1): 47. doi: 10.1186/s12937-021-00703-7. PMID: 34074289; PMCID: PMC8170788.
25. Sabico S., Al-Mashharawi A., Al-Daghri N. M., Wani K., Amer O. E., Hussain D. S., Ahmed Ansari M. G., Masoud M. S., Alokail M. S., McTernan P. G. Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo- controlled trial. Clinical Nutrition. 2019; 38 (4): 1561–1569. doi: 10.1016/j.clnu.2018.08.009. PMID: 30170781.
26. Malik M., Suboc T. M., Tyagi S., Salzman N., Wang J., Ying R., Tanner M. J., Kakarla M., Baker J. E., Widlansky M. E. Lactobacillus plantarum 299v Supplementation Improves Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men With Stable Coronary Artery Disease. Circulation Research. 2018; 123 (9): 1091–1102. doi: 10.1161/CIRCRESAHA.118.313565. PMID: 30355158; PMCID: PMC6205737.
27. Trotter R. E., Vazquez A. R., Grubb D. S., Freedman K. E., Grabos L. E., Jones S., Gentile C. L., Melby C. L., Johnson S. A., Weir T. L. Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults. Beneficial Microbes. 2020; 11 (7): 621–630. doi: 10.3920/BM2020.0039. PMID: 33161737; PMCID: PMC8773468.
28. Khongrum J., Yingthongchai P., Boonyapranai K., Wongtanasarasin W., Aobchecy P., Tateing S., Prachansuwan A., Sitdhipol J., Niwasabutra K., Thaveethaptaikul P., Phapugrangkul P., Chonpathompikunlert P. Safety and Effects of Lactobacillus paracasei TISTR 2593 Supplementation on Improving Cholesterol Metabolism and Atherosclerosis-Related Parameters in Subjects with Hypercholesterolemia: A Randomized, Double-Blind, Placebo- Controlled Clinical Trial. Nutrients. 2023; 15 (3): 661. doi: 10.3390/nu15030661. PMID: 36771367; PMCID: PMC9921995.
29. Costabile A., Buttarazzi I., Kolida S., Quercia S., Baldini J., Swann J. R., Brigidi P., Gibson G. R. An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults. PLoS One. 2017; 12 (12): e0187964. doi: 10.1371/journal.pone.0187964. PMID: 29228000; PMCID: PMC5724841.
30. Szulińska M., Łoniewski I., Skrypnik K., Sobieska M., Korybalska K., Suliburska J., Bogdański P. Multispecies Probiotic Supplementation Favorably Affects Vascular Function and Reduces Arterial Stiffness in Obese Postmenopausal Women-A 12-Week Placebo-Controlled and Randomized Clinical Study. Nutrients. 2018; 10 (11): 1672. doi: 10.3390/nu10111672. PMID: 30400570; PMCID: PMC6265939.
Supplementary files
Review
For citations:
Chervinets J.V., Stepanova E.V., Chervinets V.M., Belyaev V.S., Schukina A.O., Pogosjan A.S. The need for probiotics the using in the treatment of patients with cardiovascular diseases. Astrakhan medical journal. 2025;20(1):6-15. (In Russ.) https://doi.org/10.17021/1992-6499-2025-1-6-15
Views:
189
Email this article 